Risk Stratification and Early Conservative Treatment of Acute Pancreatitis.

Bedside Index of Severity in Acute Pancreatitis Goal-directed fluid resuscitation Pain management Prophylactic antibiotics Systemic inflammatory response syndrome

Journal

Visceral medicine
ISSN: 2297-4725
Titre abrégé: Visc Med
Pays: Switzerland
ID NLM: 101681546

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 03 01 2019
accepted: 28 01 2019
entrez: 14 6 2019
pubmed: 14 6 2019
medline: 14 6 2019
Statut: ppublish

Résumé

Acute pancreatitis (AP) is a potentially life-threatening common gastrointestinal disorder with increasing incidence around the globe. Although the majority of cases will take an uneventful, mild course, a fraction of patients is at risk of moderately severe or severe pancreatitis which is burdened with substantial morbidity and mortality. Early identification of patients at risk of a severe disease course and an adopted treatment strategy are crucial to avoid adverse outcomes. In this review we summarize the most recent concepts of severity grading in patients diagnosed with AP by adopting recommendations of current guidelines and discussing them in the context of the available literature. The severity of AP depends on the presence of local and/or systemic complications and organ failure. To predict the severity early in the disease course, host-specific factors (age, comorbidities, body mass index), clinical risk factors (biochemical and physiological parameters and scoring systems), as well as the response to initial therapy need to be considered and revisited in the short term. Depending on the individual risk and comorbidity the initial treatment can be guided, which will be discussed in the second part of this review. Predicting the severity of AP and adapting the individual treatment strategy requires multidimensional risk assessment and close observation during the early phase of AP development.

Sections du résumé

BACKGROUND BACKGROUND
Acute pancreatitis (AP) is a potentially life-threatening common gastrointestinal disorder with increasing incidence around the globe. Although the majority of cases will take an uneventful, mild course, a fraction of patients is at risk of moderately severe or severe pancreatitis which is burdened with substantial morbidity and mortality. Early identification of patients at risk of a severe disease course and an adopted treatment strategy are crucial to avoid adverse outcomes.
SUMMARY CONCLUSIONS
In this review we summarize the most recent concepts of severity grading in patients diagnosed with AP by adopting recommendations of current guidelines and discussing them in the context of the available literature. The severity of AP depends on the presence of local and/or systemic complications and organ failure. To predict the severity early in the disease course, host-specific factors (age, comorbidities, body mass index), clinical risk factors (biochemical and physiological parameters and scoring systems), as well as the response to initial therapy need to be considered and revisited in the short term. Depending on the individual risk and comorbidity the initial treatment can be guided, which will be discussed in the second part of this review.
KEY MESSAGE CONCLUSIONS
Predicting the severity of AP and adapting the individual treatment strategy requires multidimensional risk assessment and close observation during the early phase of AP development.

Identifiants

pubmed: 31192241
doi: 10.1159/000497290
pii: vis-0035-0082
pmc: PMC6514505
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

82-89

Références

Eur J Clin Invest. 1992 Mar;22(3):200-3
pubmed: 1582445
World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):158-68
pubmed: 25133018
World J Surg. 2006 Sep;30(9):1713-21
pubmed: 16927057
Gut. 2019 Jun;68(6):1044-1051
pubmed: 29950344
Lancet. 2015 Jul 4;386(9988):85-96
pubmed: 25616312
Pancreas. 2002 Apr;24(3):223-7
pubmed: 11893928
Gastroenterology. 2009 Jul;137(1):129-35
pubmed: 19344722
Gut. 2017 Aug;66(8):1531-1532
pubmed: 27849560
N Engl J Med. 2016 Nov 17;375(20):1972-1981
pubmed: 27959604
J Inflamm Res. 2018 Mar 09;11:77-85
pubmed: 29563826
Arch Intern Med. 2011 Apr 11;171(7):669-76
pubmed: 21482842
Crit Care Med. 2001 Jan;29(1):63-9
pubmed: 11176162
Br J Surg. 1989 Mar;76(3):268-72
pubmed: 2720324
J Antimicrob Chemother. 2013 Mar;68(3):715-8
pubmed: 23148204
Gut. 2013 Jan;62(1):102-11
pubmed: 23100216
J Clin Gastroenterol. 2000 Jun;30(4):343-56
pubmed: 10875461
Pancreatology. 2009;9(5):601-14
pubmed: 19657215
Pancreatology. 2002;2(2):104-7
pubmed: 12123089
Pancreas. 2010 Nov;39(8):1226-30
pubmed: 20531240
Pancreatology. 2003;3(2):115-27
pubmed: 12748420
Chin Med J (Engl). 2009 Jan 20;122(2):169-73
pubmed: 19187641
Clin Gastroenterol Hepatol. 2011 Aug;9(8):710-717.e1
pubmed: 21645639
Pancreas. 2000 May;20(4):367-72
pubmed: 10824690
HPB Surg. 2013;2013:367581
pubmed: 24204087
Eur J Gastroenterol Hepatol. 2013 Jul;25(7):784-9
pubmed: 23492986
J Immunol. 1995 Aug 1;155(3):1428-33
pubmed: 7636208
Mol Biol Rep. 2013 Oct;40(10):5931-41
pubmed: 24072654
Clin Gastroenterol Hepatol. 2014 Jun;12(6):997-1002
pubmed: 24183957
Clin Gastroenterol Hepatol. 2009 Nov;7(11):1247-51
pubmed: 19686869
Gastroenterology. 2019 Jan;156(1):254-272.e11
pubmed: 30315778
Pancreas. 2017 Apr;46(4):482-488
pubmed: 28196021
Pancreas. 2018 Jan;47(1):87-91
pubmed: 29215544
Crit Care Res Pract. 2013;2013:897107
pubmed: 23662207
N Engl J Med. 2014 Oct 16;371(16):1496-506
pubmed: 25272316
Front Immunol. 2017 Jan 17;8:15
pubmed: 28144242
Chin Med J (Engl). 2010 Jul;123(13):1639-44
pubmed: 20819621
World J Gastroenterol. 2013 Apr 7;19(13):2044-52
pubmed: 23599623
Am J Gastroenterol. 2010 Feb;105(2):435-41; quiz 442
pubmed: 19861954
Z Gastroenterol. 1986 Feb;24(2):100-9
pubmed: 2421494
Gut. 1998 Mar;42(3):431-5
pubmed: 9577354
N Engl J Med. 2014 Nov 20;371(21):1983-93
pubmed: 25409371
Turk J Gastroenterol. 2016 Mar;27(2):192-6
pubmed: 27015624
Am J Gastroenterol. 2001 Jul;96(7):2081-5
pubmed: 11467635
Crit Care. 2013 Oct 21;17(5):R249
pubmed: 24144138
Gut. 2013 Mar;62(3):430-9
pubmed: 22490516
Gastroenterology. 2018 Mar;154(4):1096-1101
pubmed: 29409760
Gut. 1984 Dec;25(12):1340-6
pubmed: 6510766
Hepatobiliary Pancreat Dis Int. 2006 May;5(2):294-9
pubmed: 16698595
Trials. 2016 Jan 05;17:5
pubmed: 26729193
Gastroenterology. 2018 Feb;154(3):704-718.e10
pubmed: 29079517
Pancreas. 2011 May;40(4):547-50
pubmed: 21499208
N Engl J Med. 2006 May 18;354(20):2142-50
pubmed: 16707751
Pancreatology. 2013 Jul-Aug;13(4 Suppl 2):e1-15
pubmed: 24054878
Gastroenterology. 2019 May;156(7):1951-1968.e1
pubmed: 30660731
Surg Gynecol Obstet. 1974 Jul;139(1):69-81
pubmed: 4834279
Dig Dis Sci. 2004 Nov-Dec;49(11-12):1946-52
pubmed: 15628731
Gut. 2008 Dec;57(12):1698-703
pubmed: 18519429
Br Med J (Clin Res Ed). 1984 May 19;288(6429):1494-5
pubmed: 6426616

Auteurs

Michał Żorniak (M)

Department of Gastroenterology, Medical University of Silesia, Katowice, Poland.

Georg Beyer (G)

Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.

Julia Mayerle (J)

Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.

Classifications MeSH